UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

 

 

Date of Report (Date of earliest event reported) August 25, 2015

 

Kewaunee Scientific Corporation
(Exact name of registrant as specified in its charter)

 

Delaware 0-5286 38-0715562

(State or other jurisdiction 

of incorporation)

(Commission 

File Number)

(I.R.S. Employer 

Identification No.)

  

2700 West Front Street

Statesville, North Carolina

28677
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code   704-873-7202

 

N/A
(Former name or former address, if changed since last report.)

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

  

Item  2.02 Results of Operations and Financial Condition

  

On August 25, 2015, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter ended July 31, 2015. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

  

 

Item  9.01 Financial Statements and Exhibits

  

  (d) Exhibits:

  

  Exhibit No.  
        99.1 Press Release of Kewaunee Scientific Corporation dated August 25, 2015

  

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

 

      (Registrant)
      Kewaunee Scientific Corporation
       
Date:  August 25, 2015      /s/ D. Michael Parker
     

D. Michael Parker

Senior Vice President, Finance

      Chief Financial Officer

 

 

 



Exhibit 99.1
 

Kewaunee Scientific Reports Results for First Quarter

STATESVILLE, N.C., Aug. 25, 2015 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported results for its first quarter ended July 31, 2015.

Sales for the quarter were $31,089,000, a 2% increase from sales of $30,534,000 in the prior year. Domestic sales for the quarter were $24,315,000, up slightly from sales of $24,248,000 in the first quarter of last year. International sales for the quarter were $6,774,000, up 8% from sales of $6,286,000 in the first quarter last year.

Net earnings for the quarter were $940,000, or $0.35 per diluted share, as compared to net earnings of $1,234,000, or $0.47 per diluted share, in the first quarter last year. Earnings for the quarter were unfavorably impacted by the shipments of the remaining orders in the backlog that were bid in the prior year at extremely competitive pricing. This impact was due to a major competitor exiting the marketplace, and to a lesser extent, by a higher effective income tax rate.

In-coming orders for the Domestic business were strong during the quarter, as opportunities increased from the improving marketplace for laboratory furniture and scientific equipment in the United States. The Company continues to see and pursue new opportunities in the International markets, particularly in the growth markets of India and the Middle East, although the timing of international incoming orders continues its unevenness from quarter-to-quarter.

The order backlog was $86.7 million at July 31, 2015, as compared to $82.7 million at July 31, 2014, and $90.1 million at April 30, 2015. An increase in the Domestic backlog was offset by shipments of several large international orders during the quarter.

The Company's balance sheet and financial condition remain strong. Unrestricted cash on hand was $2.9 million at the end of the quarter, as compared to $4.4 million at the end of the first quarter last year. Cash of $888,000 was used during the current quarter for the final annual installment toward the purchase of the minority interest in one of the Company's Asia subsidiaries. Working capital was $28.5 million, as compared to $27.5 million at the end of the first quarter last year. Short-term debt and interest rate swaps were $4.9 million at the end of the quarter, as compared to $5.2 million at the end of the first quarter last year, and total bank borrowings and interest rate swaps were $9.0 million, as compared to $9.7 million at the end of the first quarter last year.

"In our Domestic business, incoming orders continued to be strong during the quarter, and profit margins improved over those of the past two quarters," said David M. Rausch, Kewaunee's President and Chief Executive Officer. "Our International business continues to see project opportunities globally from our expanded sales organization and the continued strengthening of the Kewaunee brand worldwide.

"Looking forward, I remain optimistic we will continue to experience sales growth in fiscal year 2016. I also expect earnings to improve this fiscal year as the United States economy continues its recovery and the marketplace adjusts to the impact of the former competitor leaving the industry. My optimism is also based on our strong order backlog and expectations that our International business will continue its long-term progress."

About Kewaunee Scientific

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.

The Company's corporate headquarters is located in Statesville, North Carolina. Direct sales offices are located in the United States, India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company's China headquarters, sales office, and assembly operation are located in Suzhou Industrial Park, China. Kewaunee Scientific's website is located at http://www.kewaunee.com.

This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: D. Michael Parker
704/871-3290

Kewaunee Scientific Corporation

Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)








Three months ended



July 31,



2015


2014

Net sales


$    31,089


$    30,534

Cost of products sold


25,246


24,386

Gross profit


5,843


6,148

Operating expenses


4,319


4,348

Operating earnings


1,524


1,800

Other income


102


126

Interest expense


(92)


(81)

Earnings before income taxes


1,534


1,845

Income tax expense


571


585

Net earnings


963


1,260

Less: net earnings attributable to the noncontrolling interest


23


26

Net earnings attributable to Kewaunee Scientific Corporation


$         940


$      1,234






Net earnings per share attributable to





    Kewaunee Scientific Corporation stockholders





       Basic


$0.36


$0.47

       Diluted


$0.35


$0.47






Weighted average number of common shares outstanding





       Basic


2,630


2,620

       Diluted


2,659


2,651











Kewaunee Scientific Corporation

Condensed Consolidated Balance Sheets

(in thousands)








July 31,


April 30,



2015


2015

Assets


(Unaudited)



Cash and cash equivalents


$      2,899


$      3,044

Restricted Cash


1,964


2,276

Receivables, less allowances


28,117


29,106

Inventories


13,970


12,745

Prepaid expenses and other current assets


2,521


1,591

    Total Current Assets


49,471


48,762

Net property, plant and equipment


14,374


14,523

Other assets


6,231


6,205

Total Assets


$    70,076


$    69,490






Liabilities and Equity





Short-term borrowings and interest rate swaps


$      4,901


$      4,955

Current portion of long-term debt


421


421

Accounts payable


11,760


11,232

Other current liabilities


3,866


4,447

    Total Current Liabilities


20,948


21,055

Other non-current liabilities


13,320


13,236

    Total Liabilities


34,268


34,291

Noncontrolling interest


268


323

Kewaunee Scientific Corporation stockholders' equity


35,540


34,876

    Total Equity


35,808


35,199

Total Liabilities and Stockholders's Equity


$    70,076


$    69,490



Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Kewaunee Scientific Charts.